IIR 06-062
Inappropriate Drug Use for Seniors: Should VA adopt new HEDIS measures
Mary Jo V Pugh, PhD EdM MA South Texas Health Care System, San Antonio, TX San Antonio, TX Funding Period: July 2007 - June 2011 |
BACKGROUND/RATIONALE:
Prevention and recognition of drug-related problems in the elderly as principal health care safety issues for this decade. Successful interventions cannot be developed without valid definitions of potentially inappropriate prescribing in the elderly (PIPE). The National Committee on Quality Assurance (NCQA) defined PIPE using two measures incorporated into future Health Plan Employer Data and Information Sets (HEDIS): specific drugs to avoid (High Risk Medications in the Elderly; HRME), and clinically relevant drug-disease interactions (Rx-DIS). OBJECTIVE(S): Objective 1: Assess the association between HRME and Rx-DIS exposure and general outcomes measures. Objective 2: Assess the association between HRME and Rx-DIS exposure and patient outcomes more specific to PIPE such as fall-related injuries. Objective 3: Develop PIPE-specific utilization measures and assess their association with HRME and Rx-DIS exposure. Objective 4: Identify the extent to which VA hospitalizations are caused by adverse drug events associated with HRME or Rx-DIS exposure. For these objectives, we hypothesized that exposure to HRME and Rx-DIS would be associated with increased risk of adverse outcomes. METHODS: This retrospective database study examined exposure to drugs included in the HRME and Rx-DIS measures in FY06, and outcomes for 12 months following that exposure. Using national VA inpatient and outpatient data, we first identified Veterans who were 65 years of age in FY06, and who received VA care between FY04-06 to assess HRME. A sub-sample of individuals with conditions relevant to Rx-DIS (dementia, falls/hip fracture and chronic renal failure) was identified using NCQA criteria. VA Pharmacy (PBM) data were used to define HRME and Rx-DIS exposure based on NCQA criteria. We examined outcomes only among individuals having new exposure compared to no exposure; those with chronic exposure were excluded from analyses. Outcomes included general adverse outcomes (mortality, emergency [ER]/hospital care), outcomes more specific to PIPE, and PIPE-specific outcomes, developed using an expert consensus process. We conducted hierarchical multivariable logistic regression analyses to assess the relationship of HRME and Rx-DIS measures with adverse outcomes. To minimize confounding, analyses controlled for disease burden. For more specific and PIPE-specific outcomes we also controlled for similar events prior to exposure. We also stratified analyses focusing on patients with similar disease conditions/medication patterns to gain a better understanding of the impact of PIPE in similar types of patients. Finally, we conducted a fine grained analysis using medical chart abstraction of 1000 randomly selected VA hospitalizations to determine the extent to which unplanned hospitalizations were precipitated by an adverse drug event (ADE; identified by two clinical pharmacists using the Naranjo method). For those ADE-related hospitalizations, we further examined the extent to which the ADE was caused by HRME/Rx-DIS exposure. Odds ratios (OR) below are adjusted for potential confounders. FINDINGS/RESULTS: Among the 1,780,787 veterans who met inclusion criteria, 276,825 (15.5%) had prevalent HRME exposure in FY06; exposure was incident for 80,475 (4.5% of cohort). Of the 305,041 older veterans with dementia, falls, and acute renal failure, the one-year prevalence of HEDIS Rx-DIS exposure was 15.2%; prevalence was 20.2% for dementia, 16.2% for falls, and 8.5% for chronic renal failure; the overall incidence of Rx-DIS was 3.2%. Analyses examining mortality and general ER/hospital care found that HRME was significantly associated with subsequent mortality (OR 1.60, [1.54-1.67]) and ER/hospital care (2.54, [2.48-2.60]). Similar results were found for mortality with regard to Rx-DIS (1.61, [1.52-1.71]) and while statistically significant, the effect size for ER/hospital care was small (1.08, [1.01-1.16]). Analyses of of more specific outcomes indicated that incident HRME exposure was associated with an increased risk of emergency or hospital care for falls and fall related injuries (2.69 [2.64-2.74]). Analyses of PIPE-specific outcomes by drug group found that HRME exposure was associated with PIPE-specific adverse outcomes for cardiac medications (5.12 [1.75-15.07]), skeletal muscle relaxants (2.6 [2.23-3.25]), opioids (2.47 [1.92-3.17]), antihistamines (1.49 [1.42-1.55]), and gastrointestinal antispasmodics (1.47 [1.11-1.95]). The only commonly used drug group that did not have a significant association with condition-specific adverse outcomes was non-steroidal anti-inflammatory drugs (tramadol). There was a significant association between Rx-DIS and PIPE-specific outcomes for those with dementia (1.29 [1.11-1.51]) but not for those with chronic renal failure (0.97 [0.75-1.25]). The direction of the significant effect for falls (0.47 [0.41-0.53]) was opposite of what was expected. Of 1000 randomly selected hospitalizations, 678 were unplanned admissions. Seventy ADEs involving 113 drugs occurred in 68 (10%) veterans; of these, 38.6% were preventable. The most common ADEs that occurred were bradycardia (n=6; beta blockers, digoxin), hypoglycemia (n=6; sulfonylureas not included in HRME, insulin), falls (n=6; antidepressants, ACE-inhibitors), and mental status changes (n=6; anticonvulsants, benzodiazepines not included in HRME). Only one ADE-related hospitalization was associated with HRME exposure (GI antispasmodic associated constipation), and two ADE-related hospitalizations for ibuprofen associated acute renal failure (Rx-DIS). Using multivariable logistic regression and controlling for potential confounders, polypharmacy (9+ and 5-8 medications/year) was associated with an increased risk of ADEs (3.90 [1.43-10.61] and 2.85 [1.03-7.85] respectively). IMPACT: Data indicate that exposure to HRME/Rx-DIS is lower than NCQA's assessment using Medicare data, and that exposure diminished over the time of this study, which is an indicator of improved quality of care. While large database analyses largely supported the link between exposure and adverse outcomes, analyses based on medical chart abstraction found no relationship between ADE-related hospitalizations and HRME/Rx-DIS. It is, however, possible that the small sample size limited the power to detect significant differences. Findings from the chart abstraction are consistent with previous research indicating specific drugs (e.g., warfarin, short half-life benzodiazepines) and drug disease interactions (NSAIDs in peptic ulcer disease) NOT included in the HRME/ Rx-DIS measures are more tightly linked with adverse outcomes than many medications currently included in these measures. These findings are being used to re-assess the HRME and Rx-DIS measures. For instance, the NCQA is considering the addition of short-half-life benzodiazepines to the HRME measure, and adding peptic ulcer disease/ NSAIDs to the Rx-DIS measure based in part on these findings. It is possible that these data will provide impetus to further re-evaluate medications included in the HRME and Rx-DIS measures. External Links for this ProjectDimensions for VADimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.Learn more about Dimensions for VA. VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address. Search Dimensions for this project PUBLICATIONS:Journal Articles
DRA:
Aging, Older Veterans' Health and Care, Health Systems
DRE: Epidemiology Keywords: none MeSH Terms: none |